Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 3/20 | 0.64 |
| ▸ | CCKAR | P32238 | 1/20 | 0.64 |
| ▸ | PSEN1 | P49768 | 15/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 15/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 15/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 15/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 15/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 15/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13502678 | 0.90 | PSEN1 (0.66) | CCKBRCCKARPSEN1PSEN2APH1B | |
| SCHEMBL13502737 | 0.88 | PSEN1 (0.58) | CCKBRCCKARPSEN1PSEN2APH1B | |
| SCHEMBL13675154 | 0.87 | KCNH2 (0.66) | CCKBRCCKARPSEN1PSEN2APH1B | |
| SCHEMBL13502736 | 0.85 | PSEN1 (0.57) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13869684 | 0.84 | SCN9A (0.58) | CCKBRCCKARPSEN1PSEN2APH1B | |
| SCHEMBL13675241 | 0.84 | PSEN1 (0.53) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13675304 | 0.84 | PSEN1 (0.58) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13547426 | 0.84 | PSEN1 (0.54) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13502739 | 0.84 | PSEN1 (0.58) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13869423 | 0.83 | PSEN1 (0.60) | CCKBRCCKARPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | CCKBR 2226/4885CCKAR 3230/4885PSEN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.